2021/03/30
(SHANGHAI, March 30, 2021) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 (“Reporting Period”).
Read more2021/02/02
NEW YORK & SHANGHAI -- Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
Read more2020/12/02
SHANGHAI, December 2, 2020 -- WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, a global business research and consulting firm. This marks the fourth consecutive year WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.
Read more2020/10/29
SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2020 ("Reporting Period").
Read more2020/08/13
(SHANGHAI, August 13, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its reviewed financial results for the first half of 2020 (Reporting Period).
Read more